Deutsch | English | Français - CHF | EUR | USD
Analysen | Arzt | Interaktionen | Medikamente | MiGel | Services | Spital | Zulassungsinhaber
Sie befinden sich in - Neuregistrierungen - Fachinformation zu Bicalutamid Sandoz 50 mg
Fachinformation zu Bicalutamid Sandoz®:Sandoz Pharmaceuticals AG
Vollst. FachinformationDDDDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
Reg.InhaberStand d. Info.
L02BB03 - BicalutamideATC-DDD Version 2007. Source: WHO
L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L02 - ENDOCRINE THERAPY

Only preparations used specifically in the treatment of neoplastic diseases are classified in this group. This means that some strengths may be classified in this group, while remaining strengths are classified in G03 - Sex hormones and modulators of the genital system or H01CA - Gonadotropin-releasing hormones.

The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).

L02BB03 - Bicalutamide
StärkeAdm.RouteNote
50 mgO
LGPL2009 ywesee.com, Commit-ID
Hilfe | FAQ | Anmeldung | Kontakt | Home